BIGBEAR
PHARMACEUTICALS
Ponatinib is a tyrosine kinase inhibitor that exerts its effect by selectively inhibiting the activities of BCR-ABL fusion protein and various other kinases.
AuthenticGuaranteeFast DeliveryPrivacy FDA Approval of New Indication (December 2020)In December 2020, the U.S. FDA approved the supplemental New Drug Application (sNDA) for Iclusig (ponati···【Read More】
Update: 05 Mar,2026Source: Haiou HealthViews: 71
Phase 3 PhALLCON Trial OverviewTakeda recently announced results from the randomized, international, open‑label, multicenter Phase 3 PhALLCON trial, w···【Read More】
Update: 05 Mar,2026Source: Haiou HealthViews: 72
Copyright2024@ BIGBEAR All right reserved BIGBEAR
